|This article needs additional citations for verification. (June 2012)|
|Traded as||BSE: 524715
|Headquarters||Mumbai, Maharashtra, India|
|Key people||Israel Makov
|Products||Pharmaceuticals, generic drugs|
|Revenue||80.05 billion (US$1.3 billion) (2012)|
|Net income||29.72 billion (US$480 million) (2012)|
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is an multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. The company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancers, steroids, peptides, sex hormones, and controlled substances.
Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Kolkata with five products to treat psychiatry ailments. Cardiology products were introduced in 1987 followed by gastroenterology products in 1989. Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, gastroenterology and nephrology. Some of the top brands of the company include pantocid, susten, aztor, gemer, repace, glucored, strocit, clopilet and cardivas. Over 57% of Sun Pharma sales are from markets outside India, primarily in the US. Manufacturing is across 23 locations, including the US, Canada, Brazil, Mexico and Israel. In the US, the company markets over 200 generics, with another 150 awaiting approval from the U.S. Food and Drug Administration (FDA).
Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times. The founding family continues to hold a majority stake in the company. Today Sun Pharma is the third largest and the most profitable pharmaceutical company in India as well as the largest pharmaceutical company by market capitalisation on the Indian exchanges. The Indian pharmaceutical industry has become the third largest producer in the world in terms of volumes and is poised to grow into an industry of $20 billion in 2015 from the current turnover of $12 billion. In terms of value India still stands at number 14 in the world.
A large part of SunE Pharma’s growth can be attributed to a number of key acquisitions over the last two decades. In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U.S. FDA approved today. In 1997, Sun acquired Tamil Nadu Dadha Pharmaceuticals Limited (TDPL) based in Chennai, for their strong gynaecology and oncology brands as well as their API and dosage form plant. Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.
In 1998, Sun acquired a number of respiratory brands from Natco Pharma. Other notable acquisitions include Milmet Labs and Gujarat Lyka Organics (1999), Pradeep Drug Company (2000), Phlox Pharma (2004), a formulation plant at Bryan, Ohio and ICN, Hungary from Valeant Pharma and Able Labs (2005), and Chattem Chemicals (2008) In 2012, Sun announced acquisitions of two US companies: DUSA Pharmaceuticals Inc. and URL Pharma, Inc..
Sun Pharma's Board of Directors include:
- Israel Makov: Chairman
- Dilip Shanghvi: Managing Director
- Sudhir V. Valia: Executive Director
- Sailesh T. Desai: Executive Director
- S. Kalyanasundaram: Chief Executive Officer
- Hasmukh S. Shah: Non Executive Independent Director
- Keki M. Mistry: Non Executive Independent Director
- Ashwin Dani: Non Executive Independent Director
- S. Mohanchand Dadha: Non Executive Independent Director
- Dr. Kajal Sinha: Independent Leading Partner
In 2007, Sun Pharma demerged its R&D arm and listed it separately on the stock market as the Sun Pharma Advanced Research Company Ltd. (NSE: SPARC, BSE: 532872). In 2011, SPARC declared revenue of Rs. 580 million. SPARC focuses on new chemical entities (NCE) research and new drug delivery systems (NDDS).
- Sun Pharma Annual Report
- Sun Pharma Businessweek Profile
- Sun Pharma Investor Presentation 2011
- Crisil Ratings
- Corporate Website: Acquisitions
- Corporate Website: Board of Directors
- SPARC Financial Results 2011
- SPARC Corporate Website